Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 1, 1-8, January 2006; doi:10.1634/theoncologist.11-1-1
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giacinti, L.
Right arrow Articles by Giordano, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giacinti, L.
Right arrow Articles by Giordano, A.

Epigenetic Information and Estrogen Receptor Alpha Expression in Breast Cancer

Laura Giacintia,b, Pier Paolo Claudioa, Massimo Lopezb, Antonio Giordanoa,c

a Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA; b Division of Medical Oncology B, Regina Elena Cancer Institute, Rome, Italy; c Department of Human Pathology and Oncology, Laboratory of Biomedical Technology and Oncology, Siena, Italy

Key Words. Breast cancer • Gene expression regulation • Estrogen receptors • Anticancer drug combinations

Correspondence: Antonio Giordano, M.D., Ph.D., Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, BioLife Sciences Bldg. 333, Temple University, 1900 North 12th Street, Philadelphia, Pennsylvania 19122-6009, USA. Telephone: 215-204-9520; Fax: 215-204-9522; e-mail: giordano{at}temple.edu

In industrialized countries, breast cancer is the most common tumor in women. The tumor expression of estrogen receptors (ERs) is a very important marker for prognosis and a marker that is predictive of response to endocrine therapy. The loss of ER expression portends a poor prognosis and, in a significant fraction of breast cancers, this repression is a result of the hypermethylation of CpG islands within the ER-{alpha} promoter. Hypermethylation is one of the best known epigenetic events in mammalian cells. Over the last few years, many studies have found that other epigenetic events, such as deacetylation and methylation of histones, are involved in the complex mechanism that regulates promoter transcription. The exact interplay of these factors in transcriptional repression activity is not yet well understood. Inhibitors of some of these are currently being studied as new drugs able to restore ER-{alpha} protein expression in ER-{alpha}–negative breast cancer cells and to promote apoptosis and differentiation. Demethylating agents and histone deacetylase (HDAC) inhibitors are candidates for becoming potent new drugs in cancer therapy. This paper reviews the current understanding of the role of epigenetic information in the development of cancer and its significance in breast cancer as predictive markers of ER status and as new targets of anticancer therapy.




This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. M. Gaudet, M. Campan, J. D. Figueroa, X. R. Yang, J. Lissowska, B. Peplonska, L. A. Brinton, D. L. Rimm, P. W. Laird, M. Garcia-Closas, et al.
DNA Hypermethylation of ESR1 and PGR in Breast Cancer: Pathologic and Epidemiologic Associations
Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 3036 - 3043.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. P. Pandey and D. Picard
miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor {alpha} mRNA
Mol. Cell. Biol., July 1, 2009; 29(13): 3783 - 3790.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
Y. Yamagata, H. Asada, I. Tamura, L. Lee, R. Maekawa, K. Taniguchi, T. Taketani, A. Matsuoka, H. Tamura, and N. Sugino
DNA methyltransferase expression in the human endometrium: down-regulation by progesterone and estrogen
Hum. Reprod., May 1, 2009; 24(5): 1126 - 1132.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
E. Sonestedt, M. I. L. Ivarsson, S. Harlid, U. Ericson, B. Gullberg, J. Carlson, H. Olsson, H. Adlercreutz, and E. Wirfalt
The Protective Association of High Plasma Enterolactone with Breast Cancer Is Reasonably Robust in Women with Polymorphisms in the Estrogen Receptor {alpha} and {beta} Genes
J. Nutr., May 1, 2009; 139(5): 993 - 1001.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. E. Ford, E. J. Ekstrom, and T. Andersson
From the Cover: Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells
PNAS, March 10, 2009; 106(10): 3919 - 3924.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. D. Adams, K. P. Claffey, and B. A. White
Argonaute-2 Expression Is Regulated by Epidermal Growth Factor Receptor and Mitogen-Activated Protein Kinase Signaling and Correlates with a Transformed Phenotype in Breast Cancer Cells
Endocrinology, January 1, 2009; 150(1): 14 - 23.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo
Advances in Breast Cancer: Pathways to Personalized Medicine
Clin. Cancer Res., December 15, 2008; 14(24): 7988 - 7999.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-J. Zhao, J. Lin, H. Yang, W. Kong, L. He, X. Ma, D. Coppola, and J. Q. Cheng
MicroRNA-221/222 Negatively Regulates Estrogen Receptor{alpha} and Is Associated with Tamoxifen Resistance in Breast Cancer
J. Biol. Chem., November 7, 2008; 283(45): 31079 - 31086.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
H. Asada, Y. Yamagata, T. Taketani, A. Matsuoka, H. Tamura, N. Hattori, J. Ohgane, N. Hattori, K. Shiota, and N. Sugino
Potential link between estrogen receptor-{alpha} gene hypomethylation and uterine fibroid formation
Mol. Hum. Reprod., September 1, 2008; 14(9): 539 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
Y. Han, L. Yang, F. Suarez-Saiz, S. San-Marina, J. Cui, and M. D. Minden
Wilms' Tumor 1 Suppressor Gene Mediates Antiestrogen Resistance via Down-Regulation of Estrogen Receptor-{alpha} Expression in Breast Cancer Cells
Mol. Cancer Res., August 1, 2008; 6(8): 1347 - 1355.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Kondo, T. Toyama, H. Sugiura, Y. Fujii, and H. Yamashita
miR-206 Expression Is Down-regulated in Estrogen Receptor {alpha}-Positive Human Breast Cancer
Cancer Res., July 1, 2008; 68(13): 5004 - 5008.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Lopez-Tarruella and R. Schiff
The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm
Clin. Cancer Res., December 1, 2007; 13(23): 6921 - 6925.
[Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. D. Adams, H. Furneaux, and B. A. White
The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor-{alpha} (ER{alpha}) and Represses ER{alpha} Messenger RNA and Protein Expression in Breast Cancer Cell Lines
Mol. Endocrinol., May 1, 2007; 21(5): 1132 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
V. F. Chekhun, N. Y. Lukyanova, O. Kovalchuk, V. P. Tryndyak, and I. P. Pogribny
Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets
Mol. Cancer Ther., March 1, 2007; 6(3): 1089 - 1098.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement